Embryonic stem cell therapy-Parkinson's disease - Mitsubishi Tanabe Pharma
Latest Information Update: 25 May 2010
At a glance
- Originator Jichi Medical School; Tanabe Seiyaku
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 25 May 2010 Discontinued - Preclinical for Parkinson's disease in Japan (unspecified route)
- 11 Mar 2004 Preclinical trials in Parkinson's disease in Japan (unspecified route)